Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Elos Medtech

Industrial group in medical technology

Elos Medtech is one of Europe’s leading development and production partners for medical technology products and components. The company offers innovative products as an advanced partner including the entire life cycle of its customers' products. Elos Medtech is active in the Dental, Orthopaedics, Medical Devices and Diagnostics business segments. Financial targets include 10% revenue growth p.a and an EBIT margin of 13%. The shares are listed on Nasdaq Small Cap.

Low cyclicality products in growth areas. Strengthen focus on dental and orthopedic implants and instruments. Increased demand from medtech companies to subcontract larger portion of the value chain. Higher capacity utilization and operational leverage from investments in increased capacity in 2018 and 2019.

Dependency on customers’ decisions and commercial performance such as postponed or cancelled projects and change in product life spans. Risks also include customer specific production-rotation from external production to in-house.

SEKm 2018 2019e 2020e
Sales 645 734 796
Sales growth (%) 11,6 13,9 8,4
EBITDA 95 129 145
EBITDA margin (%) 14,8 17,6 18,2
EBIT adj 47 69 82
EBIT adj margin (%) 7,4 9,4 10,3
Pretax profit 29 54 70
EPS rep 2,59 5,06 6,21
EPS growth (%) -30,2 95,4 22,8
EPS adj 3,64 5,06 6,21
DPS 1 1,1 1,2
EV/EBITDA (x) 8,9 8,9 7,6
EV/EBIT adj (x) 18 16,6 13,4
P/E (x) 27 19,7 16
P/E adj (x) 19,2 19,7 16
EV/sales (x) 1,3 1,6 1,4
FCF yield (%) -2,4 -2,8 7,5
Dividend yield (%) 1,4 1,1 1,2
Net IB debt/EBITDA 3 2,7 2
SEKm 2018 2019e 2020e
Sales 645 734 796
COGS -466 -508 -551
Gross profit 178 226 245
Other operating items -83 -97 -100
EBITDA 95 129 145
Depreciation on tangibles -56 -60 -63
Depreciation on intangibles 0 0 0
EBITA 39 69 82
Goodwill impairment charges 0 0 0
Other impairment and amortisation 0 0 0
EBIT 39 69 82
Other financial items 0 0 0
Net financial items -10 -15 -12
Associated income 0 0 0
Other EO items 0 0 0
Pretax profit 29 54 70
Tax -8 -13 -19
Net profit 21 41 50
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders 21 41 50
EPS 2,59 5,06 6,21
EPS Adj 3,64 5,06 6,21
Total extraordinary items after tax -8,5 0 0
Tax rate (%) -26,7 -24,2 -28
Gross margin (%) 27,7 30,8 30,8
EBITDA margin (%) 14,8 17,6 18,2
EBITA margin (%) 6 9,4 10,3
EBIT margin (%) 6 9,4 10,3
Pretax margin (%) 4,4 7,3 8,7
Net margin (%) 3,2 5,6 6,3
Growth rates Y/Y 2018 2019 2020
Sales growth (%) 11,6 13,9 8,4
EBITDA growth (%) 1,3 35,2 12,2
EBIT growth (%) -8,9 77,9 18,5
Net profit growth (%) -7 95,4 22,8
EPS growth (%) -30,2 95,4 22,8
Profitability 2018 2019 2020
ROE (%) 4,8 7,7 8,7
ROE Adj (%) 6,7 7,7 8,7
ROCE (%) 4,9 7,9 8,8
ROCE Adj(%) 6 7,9 8,8
ROIC (%) 3,7 6,2 6,6
ROIC Adj (%) 4,6 6,2 6,6
Adj earnings numbers 2018 2019 2020
EBITDA Adj 104 129 145
EBITDA Adj margin (%) 16,1 17,6 18,2
EBITA Adj 47 69 82
EBITA Adj margin (%) 7,4 9,4 10,3
EBIT Adj 47 69 82
EBIT Adj margin (%) 7,4 9,4 10,3
Pretax profit Adj 37 54 70
Net profit Adj 29 41 50
Net profit to shareholders Adj 29 41 50
Net Adj margin (%) 4,6 5,6 6,3
SEKm 2018 2019e 2020e
Inventories 157 187 199
Receivables 96 128 139
Other current assets 0 0 0
Cash and liquid assets 49 21 52
Total assets 957 1064 1097
Shareholders equity 509 554 595
Minority 0 0 0
Total equity 509 554 595
Long-term debt 336 363 343
Pension debt 0 0 0
Convertible debt 0 0 0
Deferred tax 0 0 0
Other long-term liabilities 0 0 0
Short-term debt 0 0 0
Accounts payable 112 148 159
Other current liabilities 0 0 0
Total liabilities and equity 888 848 957
Net IB debt 287 343 291
Net IB debt excl. pension debt 287 343 291
Capital invested 796 896 886
Working capital 141 168 179
EV breakdown 2018 2019 2020
Market cap. diluted (m) 565 804 804
Net IB debt Adj 287 343 291
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity 0 0 0
EV 852 1146 1095
Capital efficiency (%) 2018 2019 2020
Total assets turnover (%) 71,4 72,6 73,6
Capital invested turnover (%) 84,6 86,8 89,3
Capital employed turnover (%) 81,5 83,3 85,8
Inventories / sales (%) 23,2 23,4 24,3
Customer advances / sales (%) 0 0 0
Payables / sales (%) 17,3 17,7 19,3
Working capital / sales (%) 20,1 21,1 21,8
Financial risk and debt service 2018 2019 2020
Net debt / equity (%) 56,5 61,9 48,9
Net debt / market cap (%) 51,5 42,6 36,2
Equity ratio (%) 53,1 52 54,2
Net IB debt adj. / equity (%) 56,5 61,9 48,9
Current ratio (%) 269 228 245,4
EBITDA / net interest (%) 916,3 841,8 1172,6
Net IB debt / EBITDA (%) 301,6 265,9 201,2
Interest cover (%) 374 451,9 664,5
EBITDA 95 129 145
Net financial items -10 -15 -12
Paid tax -8 -13 -19
Non-cash items 0 0 0
Cash flow before change in WC 77 101 113
Change in WC -23 -27 -11
Operating cash flow 66 73 102
CAPEX tangible fixed assets -80 -96 -41
CAPEX intangible fixed assets 0 0 0
Acquisitions and disposals 0 0 0
Free cash flow -14 -22 60
Dividend paid 0 -8 -9
Share issues and buybacks 0 0 0
Other non cash items 85 -25 0
Decrease in net IB debt 71 -55 52
Balance Sheet (SEKm) 2018 2019 2020
Goodwill 0 0 0
Indefinite intangible assets 279 284 284
Definite intangible assets 0 0 0
Tangible fixed assets 374 436 415
Other fixed assets 2 8 8
Fixed assets 655 728 707
SEKm 2018 2019e 2020e
Shares outstanding adj. 8 8 8
Fully diluted shares Adj 8 8 8
EPS 2,59 5,06 6,21
Dividend per share Adj 1 1,1 1,2
EPS Adj 3,64 5,06 6,21
BVPS 63,03 68,61 73,72
BVPS Adj 63,03 68,61 73,72
Net IB debt / share 35,6 42,5 36,1
Share price 69,2 99,6 99,6
Market cap. (m) 558 804 804
Valuation 2018 2019 2020
P/E 27 19,7 16
EV/sales 1,32 1,56 1,38
EV/EBITDA 8,9 8,9 7,6
EV/EBITA 21,9 16,6 13,4
EV/EBIT 21,9 16,6 13,4
Dividend yield (%) 1,4 1,1 1,2
FCF yield (%) -2,4 -2,8 7,5
P/BVPS 1,11 1,45 1,35
P/BVPS Adj 1,11 1,45 1,35
P/E Adj 19,2 19,7 16
EV/EBITDA Adj 8,2 8,9 7,6
EV/EBITA Adj 18 16,6 13,4
EV/EBIT Adj 18 16,6 13,4
EV/cap. employed 1 1,3 1,2
Investment ratios 2018 2019 2020
Capex / sales 12,4 13,1 5,2
Capex / depreciation 141,7 160,6 66
Capex tangibles / tangible fixed assets 21,4 22 10
Capex intangibles / definite intangibles N/A N/A N/A
Depreciation on intangibles / definite intangibles N/A N/A N/A
Depreciation on tangibles / tangibles 15,1 13,7 15,1

Equity research

Read earlier research

Media

Elos Medtech - Interview with CEO Jan Wahlström (in Swedish)
Elos Medtech - Company presentation with CEO Jan Wahlström (in Swedish)

View more media

Main shareholders - Elos Medtech

Main shareholders Share capital % Voting shares % Verified
Familjen Öster 7.4 % 22.3 % 30 Sep 2019
Lars Runmarker 5.9 % 17.6 % 30 Sep 2019
Mats Nilsson 5.4 % 15.5 % 19 Mar 2019
Bo Nilsson 4.6 % 15.2 % 30 Sep 2019
Kent Molin 5.0 % 9.0 % 30 Sep 2019
Nordea Fonder 15.3 % 6.9 % 30 Sep 2019
Svolder 11.9 % 5.3 % 30 Sep 2019
Bengt Julander 6.2 % 2.8 % 30 Sep 2019
Søren Olesen 3.0 % 1.3 % 30 Sep 2019
Nordnet Pensionsförsäkring 2.5 % 1.1 % 30 Sep 2019
Source: Holdings by Modular Finance AB

Insider list - Elos Medtech

Name Quantity Code Date
Mattias Andersson + 95 BUY 19 Jul 2019
Mattias Andersson + 905 BUY 18 Jul 2019
Jan Wahlström + 1 000 BUY 6 May 2019
Mats Nilsson Bernitz + 13 500 BUY 19 Mar 2019
Yvonne Mårtensson + 20 000 BUY 20 Jul 2018
YCM Consulting AB - 20 000 SELL 20 Jul 2018
Yvonne Mårtensson + 891 BUY 26 Apr 2018
YCM Consulting AB + 891 BUY 26 Apr 2018
Yvonne Mårtensson + 891 BUY 26 Apr 2018
YCM Consulting AB + 891 BUY 26 Apr 2018

Show More